LATEST UPDATES » Intelligent Sensor Informs You to Change a Diaper via SMS       » University of Manchester & A*STAR ongoing partnership- Joint PhD programme       » Philippines Healthcare & New Digital Platform, MyDoc.       » Tapping on ASEAN'S Healthcare Opportunities through Singapore       » ASEAN: The New Playing Field for Global Medical Device Companies       » The Burden of Great Potential: the ASEAN Economic Community & Biopharmaceuticals       » When there is no Queen in the house, Asian Hive Bees Avoid Risky Foraging for Reproduction       » XELJANZTM (Tofacitinib Citrate), A new class of treatment for Rheumatoid Arthritis Approved in Singapore      
Nagasaki University and Astellas launch collaborative research for screening new anti-dengue virus drugs for neglected tropical diseases
The Nagasaki University and Astellas Pharma Inc. announced that they have signed a collaborative research agreement to discover new drugs for the treatment of neglected tropical diseases ("NTDs") caused by dengue virus. This is the second execution of a collaborative research agreement on NTDs after the Nagasaki University and Astellas signed the previous one to discover new drugs for the treatment of NTDs caused by protozoan parasites on November 12, 2012.

NTDs, prevalent mainly in tropical areas of developing countries, are infectious diseases spread by parasites, bacteria or viruses. As it is estimated that approximately 1 billion people are affected with NTDs worldwide, NTDs are a serious healthcare issue that is being addressed on a global scale. Among them, diseases caused by dengue virus, such as dengue fever/dengue hemorrhagic fever are with high unmet medical needs for treatment and development of new therapeutic drugs. There is no existing drug to treat dengue fever/dengue hemorrhagic fever in the market as well as under development, and the effectiveness of some vaccines to prevent dengue virus currently under development is unclear at this time.

Under the collaborative agreement, the Institute of Tropical Medicine at Nagasaki University (NEKKEN), which is one of the leading research institutes on tropical infectious diseases in Japan, and Astellas will cooperate on a drug-discovery research project. Astellas will provide multiple compounds with possible anti-dengue virus activities, and NEKKEN will evaluate these compounds in experimental model of infections with dengue virus for dengue fever/dengue hemorrhagic fever. The research will be advanced with advice from Professor Kouichi Morita, M.D., Ph.D., at the Department of Virology in NEKKEN, who is a key opinion leader on tropical infection research in Japan.

The collaborative research is largely divided into two phases. In the first phase (first screening), the anti-dengue virus activities and cytotoxic activities of compounds will be measured in vitro. In the second phase (second screening), compounds found to be with anti-dengue virus activities in the first screening will be tested for in vivo activity by evaluating drug efficiency in animals infected with the dengue virus.

The Nagasaki University and Astellas will work together to accelerate the discovery of new drugs for patients suffering from dengue fever/dengue hemorrhagic fever in the world, through their collaborative research aiming to contribute to improve global public health problems.

Click here for the complete issue.


Credits to: American Chemical Society

APBN Editorial Calendar 2015
Trends and Predictions for 2015 Robotics in Healthcare Nutrition Universal Health Coverage
Start-Up Biotech Companies Preventative and Translational Medicine Biofuels ASEAN Economic Community and Asia's Life Sciences Industry
Big Data: Healthcare and Drug Development Antibody Engineering in Japan Christmas Edition
APBN Editorial Calendar 2016
Korea's Biotechnology Industry Nutrition and Allergies: Are we, Too Clean? Medical Devices and Technology: Innovation that leaves an Inspiration Tobacco Smoking: The 'Real' Cost of One Cigarette
Life-Saving Opportunities: A Guide to Regenerative Medicine Occupational Health Water Technology Olympics: Evolution of Sports
Respiratory: Seasonal flu viruses
About Us
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy